sarilumab - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.79 [0.46, 1.36]< 116%3 studies (3/-)80.4 %some concernnot evaluable moderatecrucial-
clinical improvement 1.31 [0.78, 2.21]> 172%2 studies (2/-)84.5 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.86 [1.20, 2.87]> 10%1 study (1/-)99.7 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.09 [0.87, 1.35]> 10%2 studies (2/-)76.9 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 1.26 [0.82, 1.94]< 10%2 studies (2/-)14.4 %some concernnot evaluable moderateimportant-
adverse events 1.13 [0.77, 1.67]< 10%2 studies (2/-)26.9 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.